ValuEngine cut shares of Humana (NYSE:HUM) from a buy rating to a hold rating in a report published on Tuesday.
Several other brokerages also recently weighed in on HUM. Credit Suisse Group reduced their price target on shares of Humana from $256.00 to $246.00 and set a neutral rating for the company in a research report on Friday, November 10th. BMO Capital Markets initiated coverage on shares of Humana in a research report on Monday, October 16th. They set an outperform rating and a $300.00 price target for the company. Zacks Investment Research downgraded shares of Humana from a strong-buy rating to a hold rating in a research report on Tuesday, October 17th. BidaskClub raised shares of Humana from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Finally, Cowen reaffirmed a buy rating and issued a $285.00 target price on shares of Humana in a research report on Wednesday, December 13th. Twelve analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $256.30.
Shares of Humana (HUM) opened at $245.16 on Tuesday. The firm has a market cap of $35,197.87, a P/E ratio of 21.02, a P/E/G ratio of 1.69 and a beta of 0.88. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana has a 1 year low of $186.25 and a 1 year high of $264.56.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is presently 12.59%.
Humana declared that its Board of Directors has authorized a stock buyback program on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.
In other news, VP Timothy S. Huval sold 1,382 shares of Humana stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the transaction, the vice president now owns 11,557 shares in the company, valued at approximately $2,843,484.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jody L. Bilney sold 7,054 shares of Humana stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the transaction, the senior vice president now owns 11,704 shares in the company, valued at approximately $2,901,304.56. The disclosure for this sale can be found here. Company insiders own 0.80% of the company’s stock.
Several institutional investors have recently modified their holdings of HUM. Advisors Asset Management Inc. boosted its stake in shares of Humana by 16.5% during the 2nd quarter. Advisors Asset Management Inc. now owns 3,124 shares of the insurance provider’s stock worth $752,000 after acquiring an additional 443 shares during the last quarter. Alps Advisors Inc. purchased a new position in shares of Humana during the 2nd quarter valued at $295,000. Gamco Investors INC. ET AL lifted its stake in shares of Humana by 36.2% during the 2nd quarter. Gamco Investors INC. ET AL now owns 5,175 shares of the insurance provider’s stock valued at $1,245,000 after buying an additional 1,375 shares in the last quarter. BB&T Securities LLC lifted its stake in shares of Humana by 43.9% during the 2nd quarter. BB&T Securities LLC now owns 2,520 shares of the insurance provider’s stock valued at $606,000 after buying an additional 769 shares in the last quarter. Finally, Cadence Capital Management LLC lifted its stake in shares of Humana by 0.4% during the 2nd quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after buying an additional 22 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/12/20/humana-hum-lowered-to-hold-at-valuengine.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
What are top analysts saying about Humana? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana and related companies.